Lack of IL-17 Receptor A signaling aggravates lymphoproliferation in C57BL/6 lpr mice.
Animals
Autoimmune Lymphoproliferative Syndrome
/ immunology
B-Lymphocytes
/ immunology
Cell Proliferation
HMGB1 Protein
/ metabolism
Kidney
/ immunology
Lupus Erythematosus, Systemic
/ immunology
Lymph Nodes
/ immunology
Mice
Mice, Inbred C57BL
Mice, Inbred MRL lpr
Mice, Knockout
Receptors, Interleukin-17
/ genetics
Spleen
/ immunology
T-Lymphocytes
/ immunology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 03 2019
11 03 2019
Historique:
received:
12
04
2016
accepted:
15
11
2018
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
2
10
2020
Statut:
epublish
Résumé
Defects in Fas function correlate with susceptibility to systemic autoimmune diseases like autoimmune lymphoproliferative syndrome (ALPS) and systemic lupus erythematosus (SLE). C57BL/6 lpr (B6/lpr) mice are used as an animal model of ALPS and develop a mild SLE phenotype. Involvement of interleukin-17A (IL-17A) has been suggested in both phenotypes. Since IL-17 receptor A is part of the signaling pathway of many IL-17 family members we investigated the role of IL-17 receptor signaling in disease development in mice with a B6/lpr background. B6/lpr mice were crossed with IL-17 receptor A deficient (IL-17RA KO) mice and followed over time for disease development. IL-17RA KO/lpr mice presented with significantly enhanced lymphoproliferation compared with B6/lpr mice, which was characterized by dramatic lymphadenomegaly/splenomegaly and increased lymphocyte numbers, expansion of double-negative (DN) T-cells and enhanced plasma cell formation. However, the SLE phenotype was not enhanced, as anti-nuclear antibody (ANA) titers and induction of glomerulonephritis were not different. In contrast, levels of High Mobility Group Box 1 (HMGB1) and anti-HMGB1 autoantibodies were significantly increased in IL-17RA KO/lpr mice compared to B6/lpr mice. These data show that lack of IL-17RA signaling aggravates the lymphoproliferative phenotype in B6/lpr mice but does not affect the SLE phenotype.
Identifiants
pubmed: 30858513
doi: 10.1038/s41598-019-39483-w
pii: 10.1038/s41598-019-39483-w
pmc: PMC6412096
doi:
Substances chimiques
HMGB1 Protein
0
HMGB1 protein, mouse
0
Il17ra protein, mouse
0
Receptors, Interleukin-17
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4032Références
Autoimmun Rev. 2008 Feb;7(4):317-21
pubmed: 18295737
J Intern Med. 2013 Oct;274(4):381-90
pubmed: 23808943
J Clin Invest. 2005 Feb;115(2):407-17
pubmed: 15668740
Ann Rheum Dis. 2009 Apr;68(4):604-6
pubmed: 19286907
Arthritis Res Ther. 2010;12(2):R53
pubmed: 20334681
Nat Rev Rheumatol. 2015 Jul;11(7):415-29
pubmed: 25907700
Clin Immunol. 2016 Jan;162:31-6
pubmed: 26556529
Adv Immunol. 1985;37:269-390
pubmed: 3890479
Eur J Immunol. 1997 Sep;27(9):2366-74
pubmed: 9341782
Lancet. 2014 Nov 22;384(9957):1878-1888
pubmed: 24881804
J Immunol. 2008 Sep 15;181(6):3811-7
pubmed: 18768834
Nat Rev Immunol. 2014 Sep;14(9):585-600
pubmed: 25145755
Clin Immunol. 2014 Sep;154(1):1-12
pubmed: 24858580
J Immunol. 2008 Nov 1;181(9):5948-55
pubmed: 18941183
Am J Physiol Cell Physiol. 2010 Dec;299(6):C1267-76
pubmed: 20826760
Nat Immunol. 2008 Feb;9(2):166-75
pubmed: 18157131
J Am Soc Nephrol. 2018 Apr;29(4):1210-1222
pubmed: 29483158
J Am Soc Nephrol. 2016 Dec;27(12):3666-3677
pubmed: 27030744
Autoimmun Rev. 2010 Sep;9(11):785-92
pubmed: 20647062
J Autoimmun. 2013 Sep;45:68-79
pubmed: 23871638
J Immunol. 1984 Jul;133(1):227-33
pubmed: 6609979
Immunity. 2012 Dec 14;37(6):1104-15
pubmed: 23123062
Arthritis Rheum. 2009 May;60(5):1472-83
pubmed: 19404966
J Clin Immunol. 2010 Mar;30(2):221-5
pubmed: 20107878
Curr Allergy Asthma Rep. 2014 Sep;14(9):462
pubmed: 25086580
J Immunol. 2010 May 1;184(9):4605-9
pubmed: 20308633
PLoS One. 2013;8(3):e58161
pubmed: 23472149
Mol Biol Rep. 2010 Jan;37(1):81-5
pubmed: 19347604
Blood. 2014 Feb 20;123(8):1178-86
pubmed: 24363402
Arthritis Res Ther. 2011 May 06;13(3):R71
pubmed: 21548924
J Immunol. 2013 Aug 15;191(4):1614-24
pubmed: 23858031
J Immunol. 2009 Sep 1;183(5):3160-9
pubmed: 19657089
Ann Rheum Dis. 2008 May;67(5):727-8
pubmed: 18408114
J Clin Invest. 2015 Mar 2;125(3):1098-110
pubmed: 25642769
Arthritis Rheumatol. 2015 Feb;67(2):475-87
pubmed: 25385550
Biomed Res Int. 2013;2013:861028
pubmed: 23841097
Lupus. 2008 May;17(5):394-9
pubmed: 18490415
Arthritis Res Ther. 2012 Aug 14;14(4):R184
pubmed: 22892043
J Immunol. 1989 Jul 1;143(1):103-12
pubmed: 2525144
Arthritis Rheumatol. 2014 Feb;66(2):340-9
pubmed: 24504806
J Immunol. 2008 Sep 15;181(6):4240-6
pubmed: 18768881
J Exp Med. 2003 Mar 17;197(6):711-23
pubmed: 12642603
Nat Immunol. 2005 Nov;6(11):1123-32
pubmed: 16200070
J Immunol. 2008 Dec 15;181(12):8761-6
pubmed: 19050297